Tue, May 25, 2010
Mon, May 24, 2010
Fri, May 21, 2010
Thu, May 20, 2010
Wed, May 19, 2010
Tue, May 18, 2010
Mon, May 17, 2010
Sun, May 16, 2010
Sat, May 15, 2010
Fri, May 14, 2010
Thu, May 13, 2010
Wed, May 12, 2010
[ Wed, May 12th 2010 ] - Market Wire
ENVIROTEK Becomes "SUFFER"
Tue, May 11, 2010

Cardiovascular Systems to Present at the 2010 Citi Investment Research Global Health Care Conference


//health-fitness.news-articles.net/content/2010/ .. ment-research-global-health-care-conference.html
Published in Health and Fitness on Tuesday, May 18th 2010 at 11:15 GMT by Market Wire   Print publication without navigation


ST. PAUL, Minn.--([ BUSINESS WIRE ])--Cardiovascular Systems, Inc. (Nasdaq: CSII) will present at the 2010 Citi Investment Research Global Health Care Conference at the New York Hilton, New York City. President and Chief Executive Officer David L. Martin, and Chief Financial Officer Laurence L. Betterley, will provide an overview of the company.

WHEN:

10 a.m. ET (9 a.m. CT)
Wednesday, May 26, 2010

WEBCAST:

To listen to a live webcast of the presentation, go to the investor information section of

companya™s website, [ www.csi360.com ], and click on the webcast icon. The webcast

replay will be available beginning at 12 p.m. ET the same day.
If you have any difficulty accessing the webcast, please contact

Nick Banovetz: (612) 455-1705; [ nbanovetz@psbpr.com ]

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing interventional treatment systems for vascular disease. The company's Diamondback 360® System treats calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. As many as 12 million Americans suffer from peripheral arterial disease (PAD), which is caused by the accumulation of plaque in peripheral arteries (commonly the pelvis or leg) reducing blood flow. Symptoms include leg pain when walking or at rest, and can lead to tissue loss and eventually limb amputation. In August 2007, the U.S. FDA granted 510(k) clearance for the use of the Diamondback 360 as a therapy for PAD, and CSI commenced a U.S. product launch in September 2007. Since then, more than 25,000 procedures have been performed to-date using the Diamondback 360 in leading institutions across the United States. For more information visit the company's Web site at [ www.csi360.com ].


Publication Contributing Sources